Renaissance Technologies LLC Sells 1,418,117 Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)

Renaissance Technologies LLC lowered its stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) by 99.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,471 shares of the biotechnology company’s stock after selling 1,418,117 shares during the period. Renaissance Technologies LLC owned 0.87% of Pieris Pharmaceuticals worth $113,000 as of its most recent filing with the Securities & Exchange Commission.

Insider Activity at Pieris Pharmaceuticals

In other Pieris Pharmaceuticals news, major shareholder Adar1 Capital Management, Llc purchased 3,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was purchased at an average price of $15.88 per share, for a total transaction of $47,640.00. Following the completion of the purchase, the insider now directly owns 129,574 shares of the company’s stock, valued at $2,057,635.12. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 8.89% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 16th.

Pieris Pharmaceuticals Price Performance

Shares of Pieris Pharmaceuticals stock opened at $16.55 on Monday. The stock has a market cap of $21.85 million, a price-to-earnings ratio of -1.38 and a beta of 0.67. Pieris Pharmaceuticals, Inc. has a 1 year low of $6.20 and a 1 year high of $24.80. The firm’s 50-day moving average is $16.88 and its 200 day moving average is $13.15.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share (EPS) for the quarter. Pieris Pharmaceuticals had a negative return on equity of 101.29% and a negative net margin of 39.71%.

Pieris Pharmaceuticals Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.